Usage and dosage guide for neratinib/neratinib (He Li'an)

The usage and dosage of neratinib/neratinib are highly professional, and the dosage regimen will be individually adjusted according to the disease stage and patient tolerance. In the extended adjuvant treatment of HER2-positive early breast cancer, the common recommended dose is 240 mg orally per day, that is, six 40 mg tablets of the drug, and it is recommended to take it with meals to improve drug absorption and tolerance. The treatment usually lasts for a longer period of time, up to a year, and the core goal is to reduce the risk of recurrence rather than short-term results.

In the treatment of advanced or metastatic breast cancer, neratinib is often used in combination regimens. Usually in a 21-day treatment cycle, 240 mg of neratinib is taken orally daily from days 1 to 21, and combined with capecitabine in the first 14 days of the same cycle, until disease progression or intolerable adverse reactions occur. This regimen emphasizes continuous inhibition of tumor signaling pathways and requires high patient compliance.

Diarrhea is one of the most representative drug reactions of neratinib, so overseas guidelines generally emphasize the importance of preventive treatment. If a dose escalation strategy is not adopted, loperamide is usually used concurrently on the day of the first dose, and prophylactic medication is continued for the first 56 days, and then the maintenance dose is adjusted according to bowel movements to control the number of daily bowel movements. For some patients, a dose escalation schedule of approximately two weeks can also be adopted under the guidance of a physician to improve tolerance.

In addition, for patients with severe hepatic impairment, the starting dose needs to be significantly lowered. It is usually recommended to start from 80 mg and adjust under close monitoring. Generally speaking, neratinib is not a "fixed" medication mode, but a targeted therapy drug that needs to be dynamically adjusted based on the disease stage, adverse reaction management, and liver function status. Standardized use is the key to ensuring efficacy and safety.

Reference materials:https://en.wikipedia.org/wiki/Neratinib